PSS68 Work Productivity and Activity Impairment Among Chronic Spontaneous/Idiopathic Urticaria Patients: ResultsFrom The First International Burden of Illness Study (Assure-Csu)  by Balp, M et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A427
PSS67
DoeS HealtH-RelateD Quality of life evaluation in PSoRiaSiS MatteR? 
a Review of labelS of PSoRiaSiS PRoDuctS aPPRoveD by tHe fDa anD 
tHe eMa
Acquadro C1, Perret C1, Arnould B2
1Mapi Research Trust, Lyon, France, 2Patient-Centered Outcomes - Mapi, Lyon, France
Objectives: Psoriasis is a papulosquamous skin disease characterized by recurring 
thick, itchy and dry red patches covered with silvery scales. It has been shown that 
patients with psoriasis have a reduction in their quality of life similar to patients 
with other chronic diseases, such as ischemic heart disease and diabetes. The objec-
tive of this study was to evaluate how health-related quality of life (HRQL) was taken 
into consideration in the evaluation of psoriasis products approved by the FDA and 
the EMA since 1995. MethOds: The websites of the FDA and the EMA were explored 
to identify all psoriasis products approved. PROLabels was used to identify products 
with a PRO claim in label. All corresponding clinical reviews (FDA), and assessments 
reports (EMA) were reviewed for HRQL evaluation. Results: Twenty-seven products 
have been approved since 1995 (18 FDA, nine EMA). Six products were common to 
both agencies (i.e., adalimumab, apremilast, etanercept, infliximab, secukinumab, 
ustekinumab). For the products approved by both agencies, the same clinical studies 
were submitted. PRO claims were found in nine products (eight EMA, one FDA). HRQL 
was mentioned in the label of all EMA products (mainly, improvement in QOL), but 
not the FDA’s. The Dermatology Life Quality Index (DLQI) was used for all products, 
and the SF-36 for six products. Among the eight EMA products with a HRQL claim, 
five products have been also approved by the FDA. In two cases (apremilast, usteki-
numab), the medical review was not available. Therefore, reasons for not including 
HRQL in the label could not be retrieved. For the three other products (adalimumab, 
infliximab, secukinumab), HRQL was not mentioned in the review. cOnclusiOns: 
The EMA seems to consider HRQL as a valuable endpoint in the evaluation of pso-
riasis products in contrast with the FDA. More harmonization between agencies 
might be beneficial to patients’ information.
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Objectives: The ASSURE-CSU study is an observational, non-interventional, mul-
tinational study conducted to identify and quantify the humanistic and economic 
burden of illness in inadequately controlled CSU/CIU patients. Here we summarise 
the work and activity impairment among patients enrolled in Canada, Germany, UK, 
and the Netherlands. MethOds: This study included a 1-year retrospective medical 
record abstraction, a cross-sectional patient-reported outcomes survey and a 7-day 
prospective patient diary. Adult patients with CSU/CIU inadequately controlled with 
H1-antihistamines, with disease persisting for ≥ 12 months were assessed. Patients 
completed the Work Productivity and Activity Impairment-Specific Health Problem 
(WPAI-SHP) questionnaire, and Resultswere described as mean (SD). Activity impair-
ment was assessed among all patients; only employed patients were queried about 
work impairment. Results: A total of 86, 94, 74 and 93 patients completed the 
patient diary in Canada, Germany, UK and the Netherlands, respectively. Of these, 
54.7%, 72.3%, 51.4% and 52.7% patients were currently employed, respectively. In 
the Canadian cohort, mean time loss due to absenteeism and presenteeism were 
6.0% (12.0%) and 29.8% (26.3%) with an overall work productivity impairment of 
30.6% (27.0%) and activity impairment of 38.3% (31.3%). Corresponding values for 
Germany were 7.4% (20.0%), 27.9% (25.7%), 30.5% (26.6%) and 36.4% (28.5%), respec-
tively. In UK, mean time loss due to absenteeism was 9.9% (23.2%), presenteeism 
33.1% (30.0%), overall work productivity impairment 35.3% (30.9%) and activity 
impairment 39.5% (30.3%). In the Netherlands, corresponding values were 2.3% 
(8.9%), 19.9% (25.4%), 20.7% (26.8%) and 31.0% (27.9%), respectively. The highest per-
centage of time missed due to CSU/CIU was reported in patients with moderate and 
severe CSU/CIU. cOnclusiOns: The Resultsare consistent among the countries 
and demonstrate that symptomatic patients with CSU/CIU experience a substantial 
impact on their daily activities and that many employed patients are affected at 
work by their disease.
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bAckgROund: Psoriasis is an chronic inflammatory disease of the skin affecting 
approximately 1-3% of population worldwide, almost 2% in Europe and 2.8% in 
Italy. Psoriasis has been associated with several comorbidities as arthropathy, 
permanent disfigurement), require systemic treatment. Few studies have evalu-
ated the psychosocial and quality of life impact of IH and there is currently a 
lack of data concerning the burden of disease. The present study aims to char-
acterize IH, and provide a comprehensive evaluation of the burden of disease 
on families, in Europe and in the United States. MethOds: International cross-
sectional study conducted in children newly diagnosed with IH, aged under 5 
months at diagnosis and requiring systemic treatment. The primary caregiver 
was asked to complete two self-administered questionnaires on the day of the 
consultation :the Hemangioma Family Burden (HFB) and a Family Member ques-
tionnaire Results: A total of 693 individuals participated in the study.Mean 
age ranged from 5.24 to 16.77 months with the majority of IH cases occurring 
in females. Approximately 80% of all cases were moderate or severe and the 
majority of patients (≥ 71.2%) received propranolol. Consistent across countries, 
the majority of parents (≥ 70%) reported a psychological impact resulting from 
their child’s IH but less than 10% were offered psychological support. In addi-
tion, approximately 50% of parents reported that their child’s condition affected 
their professional life. The global HFB score increased significantly (p < 0.0001) 
with increased IH severity. The majority (> 90%) of parents were satisfied with the 
care of their child and their child’s IH. cOnclusiOns: The present study, using 
the validated HFB questionnaire, provides previously unprecedented insights 
into the burden of IH, and highlights potential areas for future focus in assisting 
families.
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Objectives: Eating is a pleasure for most people in daily life. It involves not only the 
physiologic intake of nourishment but also important social, psychologic, and cul-
tural experiences. However, few studies have been assessed the impact of dysphagia 
on quality of life (QOL). Also, the association between dysphagia and perspectives of 
happiness is unknown. We aimed to examine the association between QOL and per-
spectives of happiness in middle-aged and older people with dysphagia. MethOds: 
We collected data from 138 dysphagia patients in university hospitals and clinics 
at Kyushu and Tokai area, Japan (mean age ± SD, 73 ± 11 years; range 40–98 years). 
The total of 12% in the subjects had have tube feeding. QOL was assessed using 
the dysphagia-related QOL scale which consisted of 7 domains. Happiness was 
evaluated using one item of a questionnaire. Clinical information was provided by 
medical professionals. Perspectives of happiness was categorized as “very happy,” 
“quite happy,” “neither happy/nor unhappy,” or “not at all happy.” We computed 
the mean QOL scores in each domain according to the level of happiness, adjust-
ing for age, gender and nutrient intake, by analysis of covariance. The p values for 
trend were calculated. Results: Overall, 26% reported feeling “very happy” and 
46% were “quite happy”, whereas 20% were “neither happy/nor unhappy” and 8% 
were “not at all happy.” There was no significant relationship between age, the level 
of happiness and the severity of dysphagia. The scores of “Symptom” (p= 0.04) and 
“Resignation” (p= 0.04) domains increased with decreasing the level of happiness. 
Even after statistical adjustment for activities of daily living, these associations 
remained significant. cOnclusiOns: Symptoms and resignation regarding dys-
phagia were negatively associated with happiness. The improvement of QOL may 
have the positive impact on perspectives of happiness in middle-aged and older 
people with dysphagia.
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Objectives: A 75% improvement in the Psoriasis Area and Severity Index (PASI 
75) is generally considered the clinical gold standard of treatment efficacy in 
patients with psoriasis. Outcomes for patients who achieve PASI 75 but not higher 
levels of response such as 90% or 100% PASI improvement (PASI 90 or PASI 100) 
are not fully characterized. This evaluation summarized the incremental benefits 
in outcomes such as health-related quality of life (HRQoL) of achieving complete 
or near-complete resolution of psoriasis, indicated by PASI ≥ 90 and/or Physician 
Global Assessment (PGA) score of 0, compared with lesser response. MethOds: 
A targeted literature search was conducted in the PubMed and Embase databases 
using a date limit of 10 years (January 1, 2005–March 10, 2015). Various search terms 
were used, including Medical Subject Heading (MeSH) and free-text terms. One 
reviewer performed level l screening on 328 titles and abstracts and level 2 screen-
ing on 92 full-text articles. Results: A total of 20 articles were ultimately selected 
that focused on the added value of achieving complete or near-complete resolution 
of psoriasis. Several analyses of clinical studies of adalimumab, infliximab, ixeki-
zumab, brodalumab, and mixed treatments have indicated that achieving PASI 90, 
PASI 100, and/or a PGA score of 0 yields benefits as demonstrated by significant 
improvements in patient-reported outcomes (e.g., Dermatology Life Quality Index 
score, measures of symptom severity, concomitant topical medication use) com-
pared with a lower PASI or PGA response. cOnclusiOns: This literature summary 
provides further evidence that complete or near-complete resolution in psoria-
sis is associated with better patient-reported outcomes. Accordingly, establish-
ing complete or near-complete resolution as the therapeutic goal would have a 
significant impact on HRQoL and other outcomes in patients with moderate to 
severe psoriasis.
